Amsterdam, the Netherlands, 4 November 2014. LSP (Life Sciences Partners), a leading European investor in health care, today announces that its portfolio company Nexstim was successfully listed on Nasdaq First North Finland and Nasdaq First North Sweden. Nexstim is a Finnish medical technology company that has developed a technology which allows non-invasive targeting of a specific area of the brain with high accuracy. Nexstim has pioneered the technology as a diagnostic tool for brain surgery planning. Based on the same technology platform the company has developed a device to improve rehabilitation for stroke patients. LSP has supported the company since the fund’s initial investment in 2007 and is represented on the Board of Directors of the company.
Nexstim has raised gross proceeds of EUR 15.3 million in the offering at an offer price of EUR 6.35 per share. The shares issued in the offering are expected to be registered with the Trade Register on or about 13 November 2014, and trading in the Company's shares on both marketplaces is expected to commence on or about 14 November 2014, on Nasdaq First North Finland with the ticker NXTMH and on Nasdaq First North Sweden with the ticker NXTMS.
A version of company’s press release can be found here.
Contact
Dr. René Kuijten, General Partner LSP
Dr. Anne Portwich, Partner LSP
Tel: +31 (0)20 664 55 00